TDA3 Antibody

What is the TDA3 antibody and what does it target?

TDA3 is a monoclonal antibody clone that specifically targets Ksp37 (Killer-specific secretory protein of 37 kD), also known as FGFBP2 (Fibroblast growth factor binding protein 2). This is a 37 kD Th1-specific secretory protein produced by natural killer cells, γ/δ T cells, a subset of effector CD8 T cells, and Th1 cells. The antibody is commonly available as a PE (phycoerythrin) conjugate and is of mouse IgG1, κ isotype . The target protein is secreted into serum and most Ksp37-expressing cells coexpress perforin, suggesting its involvement in cytotoxic lymphocyte-mediated immunity .

What are the verified reactivity and applications of the TDA3 antibody?

The TDA3 antibody has been quality-tested and verified for:

The antibody has been specifically quality-tested for intracellular immunofluorescent staining with flow cytometric analysis .

What is the recommended protocol for using TDA3 antibody in flow cytometry?

For optimal flow cytometric staining with the TDA3 antibody, follow this protocol:

• Sample Preparation: Prepare either isolated cells (5 μL per million cells in 100 μL staining volume) or whole blood (5 μL per 100 μL of whole blood) .

• Fixation and Permeabilization: Since Ksp37/FGFBP2 is predominantly intracellular, cells must be fixed and permeabilized using a standard intracellular staining protocol.

• Staining: Add the recommended amount of TDA3 antibody and incubate according to your established protocol (typically 20-30 minutes at room temperature in the dark).

• Washing: Wash cells with appropriate buffer to remove unbound antibody.

• Analysis: Analyze using a flow cytometer equipped with appropriate lasers for PE detection (Blue Laser 488 nm or Green/Yellow-Green Laser 532/561 nm) .

• Optimization: It is strongly recommended to titrate the antibody for optimal performance in your specific experimental system.

How should the TDA3 antibody be stored and handled to maintain activity?

For optimal preservation of antibody activity:

• Storage Temperature: Store undiluted between 2°C and 8°C .

• Light Protection: Protect from prolonged exposure to light, particularly important for PE-conjugated antibodies.

• Freeze Prevention: Do not freeze the antibody as this can damage the protein structure and fluorochrome conjugation .

• Expiration: Pay attention to the lot-specific expiration date.

• Contamination Prevention: Use sterile technique when handling to prevent microbial contamination.

• Centrifugation: Briefly centrifuge the vial before opening to collect all material at the bottom.

How can TDA3 antibody be used to study the role of Ksp37/FGFBP2 in immune responses?

The TDA3 antibody is a valuable tool for studying Ksp37/FGFBP2's role in immune responses, particularly in cytotoxic immunity. Research indicates that most Ksp37-expressing cells coexpress perforin, suggesting involvement in cytotoxic lymphocyte-mediated immunity . Advanced applications include:

• Correlation Analysis: Use multiparameter flow cytometry with TDA3 and other markers to correlate Ksp37 expression with cytotoxic activity, perforin levels, and functional outcomes.

• Disease State Analysis: Investigate changes in Ksp37 expression in various pathological conditions. Elevated Ksp37 levels have been observed in body fluids of patients with asthma and certain infectious diseases .

• Cell Type Characterization: Use TDA3 to identify and characterize specific immune cell subpopulations, particularly within NK cells, γ/δ T cells, CD8 T cells, and Th1 cells.

• Functional Studies: Combine with functional assays to determine how Ksp37 expression correlates with cytokine production, cytotoxicity, and other immune functions.

What approaches can be used to validate TDA3 antibody specificity for reliable research results?

Antibody validation is critical for generating reliable research data. A 2013 study showed that only 48% of antibodies recommended for western blotting recognized their intended protein . For TDA3 antibody validation:

• Positive and Negative Controls: Include cell types known to express or lack Ksp37/FGFBP2 (NK cells as positive; certain non-immune cells as negative).

• Blocking Experiments: Pre-incubate the antibody with recombinant Ksp37 protein to confirm that binding is inhibited when the epitope is blocked.

• siRNA Knockdown: Reduce target expression using siRNA against Ksp37/FGFBP2 and confirm reduced antibody staining.

• Third-Party Testing: Consider third-party validation as recommended for research antibodies . This provides unbiased confirmation of specificity.

• Orthogonal Methods: Confirm findings using alternative detection methods like qPCR for mRNA expression correlation.

• Cross-Reactivity Assessment: Test against related proteins to ensure specificity, particularly if working with non-human samples.

What are common issues encountered with TDA3 antibody staining and how can they be resolved?

How can researchers optimize TDA3 antibody concentration for flow cytometry experiments?

A systematic titration approach is essential for determining the optimal antibody concentration:

• Serial Dilution: Prepare a series of antibody dilutions (typically 5-7 different concentrations) starting from the manufacturer's recommended concentration.

• Staining Index Calculation: For each concentration, calculate the staining index using the formula:

  $\text{Staining Index} = \frac{\text{MFI of positive population} - \text{MFI of negative population}}{2 \times \text{standard deviation of negative population}}$

• Optimal Concentration Determination: Plot the staining index against antibody concentration. The optimal concentration will typically be at or near the peak of this curve.

• Signal-to-Noise Evaluation: Consider both separation of positive/negative populations and background levels when selecting optimal concentration.

• Lot-to-Lot Variations: Repeat titration when switching to a new antibody lot as conjugation efficiency may vary.

How does TDA3 antibody performance compare with other anti-Ksp37/FGFBP2 antibodies?

While specific comparative data for different anti-Ksp37 antibodies is limited in the search results, general principles of antibody comparison apply:

• Epitope Differences: Different antibodies may recognize distinct epitopes on Ksp37, affecting detection of post-translationally modified or truncated forms.

• Affinity Variations: Antibodies may differ in binding affinity, affecting sensitivity and signal strength.

• Clone Specificity: Monoclonal antibodies like TDA3 offer consistent epitope recognition but may be more sensitive to epitope masking compared to polyclonal alternatives.

• Application Suitability: Some antibodies may perform better in specific applications - TDA3 has been validated for intracellular flow cytometry .

A systematic comparison of different clones using standardized samples and protocols would be the most reliable approach to determine relative performance.

How can researchers apply the principles of prodrug antibody design to enhance TDA3 specificity?

Recent innovations in antibody engineering can potentially be applied to enhance TDA3 functionality:

• PAS Masking Approach: A recent study demonstrated that polypeptide sequences composed of repeated Pro, Ala, and Ser residues (PAS) can function as universal masking sequences to reduce off-target effects of antibodies . This approach could potentially be adapted to TDA3:

  • The PAS sequence can be fused to the N-terminus of the antibody via a cleavable linker

  • PAS works through steric hindrance due to its large fluid dynamic radius and disordered structure

  • The masking effect can be fine-tuned by adjusting PAS sequence length

  • The mask can be removed by cancer-related or cell-specific proteases in target environments

• Implementation Benefits:

  • Reduced background staining in non-target tissues

  • Enhanced specificity for activated immune cells

  • Potential reduction in non-specific binding during intracellular staining

This approach would require protein engineering expertise but could significantly enhance the specificity of TDA3 for detecting Ksp37 in specific cellular contexts.

How can TDA3 antibody be applied to study asthma and infectious disease mechanisms?

Ksp37/FGFBP2 levels have been found elevated in body fluids of patients with asthma and some infectious diseases . Researchers can apply TDA3 antibody to investigate these conditions through:

• Biomarker Studies: Quantify Ksp37+ cells in peripheral blood, bronchoalveolar lavage fluid, or tissues from patients versus controls.

• Cellular Source Identification: Use multi-parameter flow cytometry with TDA3 and lineage markers to identify which specific cell types contribute to elevated Ksp37 in disease states.

• Longitudinal Analysis: Monitor changes in Ksp37 expression during disease progression or treatment.

• Mechanistic Investigations: Correlate Ksp37 expression with clinical parameters, cytokine profiles, and disease severity to understand its functional significance.

• Therapeutic Response Monitoring: Assess whether Ksp37 expression changes in response to treatment, potentially serving as a biomarker of therapeutic efficacy.

What methodological considerations are important when researching Ksp37/FGFBP2 association with perforin expression?

Since most Ksp37-expressing cells coexpress perforin , investigating this relationship requires specific methodological approaches:

• Co-staining Protocol:

  • Fix and permeabilize cells thoroughly to access both intracellular proteins

  • Choose compatible fluorochromes for TDA3 (e.g., PE) and anti-perforin (e.g., FITC or APC)

  • Include single-stained controls for proper compensation

  • Optimize fixation and permeabilization protocol to preserve epitopes for both antibodies

• Quantitative Analysis:

  • Measure correlation coefficient between Ksp37 and perforin expression

  • Perform quadrant analysis to identify single and double-positive populations

  • Consider analysis of perforin expression levels within Ksp37high versus Ksp37low subpopulations

• Functional Correlation:

  • Combine phenotypic analysis with cytotoxicity assays to determine if Ksp37+Perforin+ cells show enhanced killing activity

  • Sort cell populations based on Ksp37/perforin expression patterns to test functional differences

• Technical Controls:

  • Include isotype controls matched to both antibodies

  • Perform fluorescence-minus-one (FMO) controls to accurately set gates

  • Validate co-staining with known positive control samples (e.g., activated NK cells)